Melinta Therapeutics Reports First Quarter 2018 Financial Results

Strong Product Sales Performance Across Entire Portfolio Continuing to Optimize Operations to Achieve Cost Synergies Important Achievements for Development and Discovery Efforts Including CARB-X Funding Award NEW HAVEN, Conn. , May 08, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc.

READ FULL TEXT

Leave a Reply

Your email address will not be published.